Kalaris Therapeutics (NASDAQ: KLRS) announced positive initial data from its Phase 1a trial of TH103, an investigational treatment for neovascular ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE